Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice

Journal of Bone and Mineral Metabolism

Volumn 31, Issue 1, 2013, Pages 26-33

  Yamamoto, Ryuichiro ^a   Matsushita, Masaki ^a   Kitoh, Hiroshi ^a   Masuda, Akio ^a   Ito, Mikako ^a   Katagiri, Takenobu ^b   Kawai, Tatsushi ^c   Ishiguro, Naoki ^a   Ohno, Kinji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

C2C12 myogenic cells; Fendiline hydrochloride; Fibrodysplasia ossificans progressiva; Heterotopic ossification; Perhexiline maleate

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANGINA PECTORIS AGENT; BONE MORPHOGENETIC PROTEIN 2; FENDILINE; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; PERHEXILINE MALEATE; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; GENE EXPRESSION; HETEROTOPIC OSSIFICATION; MALE; MOUSE; MUSCLE CELL; MYOGENIC CELL; NONHUMAN; OSSIFYING MYOSITIS; OSTEOBLASTIC TRANSFORMATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CALCIUM CHANNEL BLOCKERS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FENDILINE; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MICE; MICE, MUTANT STRAINS; MUSCLE CELLS; MUTATION; MYOSITIS OSSIFICANS; OSSIFICATION, HETEROTOPIC; OSTEOBLASTS; PERHEXILINE; PROMOTER REGIONS, GENETIC; SMAD PROTEINS;

EID: 84876290503     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0380-2     Document Type: Article

References (57)

1. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM (2008) Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheurmatol 22:191-205
2. Glaser DL, Rocke DM, Kaplan FS (1998) Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 346:110-116
3. Rogers JG, Geho WB (1979) Fibrodysplasia ossificans progressiva. A survey of forty-two cases. J Bone Joint Surg Am 61:909-914
4. Connor JM, Evans DA (1982) Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br 64:76-83
5. Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS (1995) Permanent heterotopic ossification at the injection site after diphtheria-tetanus- pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr 126:762-764
6. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS (2005) Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116:e654-e661
7. Kawai T, Urist MR (1988) Quantitative computation of induced heterotopic bone formation by an image analysis system. Clin Orthop Relat Res 233:262-267
8. Hayashi T, Kawai T, Ishikawa A, Kawai H, Nakano K, Takei Y, Kuroki K (2008) Histological analysis of induced cartilage on the biodegradable or nonbiodegradable membranes from immature muscular tissue in vitro. J Biomed Mater Res A 86:1048-1054
9. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525-527
10. DiCesare PE, Nimni ME, Peng L, Yazdi M, Cheung DT (1991) Effects of indomethacin on demineralized bone-induced heterotopic ossification in the rat. J Orthop Res 9:855-861
11. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405-1415
12. Rogers JG, Dorst JP, Geho WB (1977) Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr 91:1011-1014
13. Brantus JF, Meunier PJ (1998) Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 346:117-120
14. Gannon FH, Glaser D, Caron R, Thompson LD, Shore EM, Kaplan FS (2001) Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol 32:842-848
15. Kaplan FS, Tabas JA, Gannon FH, Finkel G, Hahn GV, Zasloff MA (1993) The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J Bone Joint Surg Am 75:220-230
16. Kaplan FS, Glaser DL, Shore EM, Pignolo RJ, Xu M, Zhang Y, Senitzer D, Forman SJ, Emerson SG (2007) Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am 89:347-357
17. Glaser DL, Kaplan FS (2005) Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:243-250
18. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4:33-41
19. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD (2008) BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 14:1363-1369
20. Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M (2011) Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med 17:454-460
21. Heemskerk J, Tobin AJ, Bain LJ (2002) Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA. Trends Neurosci 25:494-496
22. Abbott A (2002) Neurologists strike gold in drug screen effort. Nature 417:109
23. Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R (2002) Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells 7:949-960
24. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127:1755-1766
25. Kodaira K, Imada M, Goto M, Tomoyasu A, Fukuda T, Kamijo R, Suda T, Higashio K, Katagiri T (2006) Purification and identification of a BMP-like factor from bovine serum. Biochem Biophys Res Commun 345:1224-1231
26. Kawakami T, Uji H, Antoh M, Hasegawa H, Kise T, Eda S (1993) Squalane as a possible carrier of bone morphogenetic protein. Biomaterials 14:575-577
27. Boergermann JH, Kopf J, Yu PB, Knaus P (2010) Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol 42:1802-1807
28. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77
29. Vincent AM, Sakowski SA, Schuyler A, Feldman EL (2008) Strategic approaches to developing drug treatments for ALS. Drug Discov Today 13:67-72
30. Gerber AN, Masuno K, Diamond MI (2009) Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci USA 106:4929-4934
31. Sleigh JN, Buckingham SD, Esmaeili B, Viswanathan M, Cuppen E, Westlund BM, Sattelle DB (2011) A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds. Hum Mol Genet 20:245-260
32. Bayer R, Mannhold R (1987) Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 5:103-136
33. Nawrath H, Klein G, Rupp J, Wegener JW, Shainberg A (1998) Open state block by fendiline of L-type Ca++ channels in ventricular myocytes from rat heart. J Pharmacol Exp Ther 285:546-552
34. Orosz F, Christova TY, Ovadi J (1988) Functional in vitro test of calmodulin antagonism: effect of drugs on interaction between calmodulin and glycolytic enzymes. Mol Pharmacol 33:678-682
35. Nagano N (2006) Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 109:339-365
36. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045
37. Wada M, Nagano N (2003) Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transpl 18(Suppl 3):iii13-iii17
38. Watanabe H, Takahashi R, Tran QK, Takeuchi K, Kosuge K, Satoh H, Uehara A, Terada H, Hayashi H, Ohno R, Ohashi K (1999) Increased cytosolic Ca(2+) concentration in endothelial cells by calmodulin antagonists. Biochem Biophys Res Commun 265:697-702
39. Cheng JS, Chou KJ, Wang JL, Lee KC, Tseng LL, Tang KY, Huang JK, Chang HT, Su W, Law YP, Jan CR (2001) Fendiline mobilizes intracellular Ca2+ in Chang liver cells. Clin Exp Pharmacol Physiol 28:729-733
40. Wang J, Cheng J, Chan R, Tseng L, Chou K, Tang K, Chung Lee K, Lo Y, Jan C (2001) The anti-anginal drug fendiline increases intracellular Ca(2+) levels in MG63 human osteosarcoma cells. Toxicol Lett 119:227-233
41. Lin MC, Jan CR (2002) The anti-anginal drug fendiline elevates cytosolic Ca(2+) in rabbit corneal epithelial cells. Life Sci 71:1071-1079
42. Jorgensen NR (2005) Short-range intercellular calcium signaling in bone. APMIS Suppl 118:5-36
43. Spangler JG (2008) Bone biology and physiology: implications for novel osteoblastic osteosarcoma treatments? Med Hypotheses 70:281-286
44. Lindberg JS (2005) Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int Suppl 67:S33-S36
45. Zerbi S, Ruggiero P, Pedrini LA (2008) Massive soft tissue calcifications and cinacalcet. J Clin Endocrinol Metab 93:1121-1122
46. Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transpl 23:387-389
47. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD (1982) Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284:295-299
48. Sallustio BC, Westley IS, Morris RG (2002) Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 54:107-114
49. Fardeau M, Tome FM, Simon P (1979) Muscle and nerve changes induced by perhexiline maleate in man and mice. Muscle Nerve 2:24-36
50. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S (1984) Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057-1064
51. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ (1986) Perhexiline maleate treatment for severe angina pectoris - correlations with pharmacokinetics. Int J Cardiol 13:219-229
52. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, Hartley LH, Smith TW, Antman EM (1990) Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81:1260-1270
53. Inglis S, Stewart S (2006) Metabolic therapeutics in angina pectoris: history revisited with perhexiline. Eur J Cardiovasc Nurs 5:175-184
54. Fleckenstein-Grun G, Fleckenstein-Grun A, Byon YK, Kem KW 1978 Mechanisms of action of Ca++ antagonists in the treatment of coronary disease, with special reference to perhexiline maleate. In: Perhexiline Maleate Proceedings of a Symposium, pp 1-22
55. Kennedy JA, Unger SA, Horowitz JD (1996) Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52:273-280
56. Stanley WC (2002) Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Invest Drug 11:615-629
57. Willoughby SR, Stewart S, Chirkov YY, Kennedy JA, Holmes AS, Horowitz JD (2002) Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 23:1946-1954